Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: A phase 1b study

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 954-965

  Ribas, Antoni ^a   Gonzalez, Rene ^b   Pavlick, Anna ^c   Hamid, Omid ^d   Gajewski, Thomas F ^e   Daud, Adil ^f   Flaherty, Lawrence ^g   Logan, Theodore ^h   Chmielowski, Bartosz ^a   Lewis, Karl ^b   Kee, Damien ⁱ   Boasberg, Peter ^d   Yin, Ming ^j   Chan, Iris ^j   Musib, Luna ^j   Choong, Nicholas ^j   Puzanov, Igor ^k   McArthur, Grant A ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Angeles Clinic and Research Institute   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j GENENTECH INC   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; B RAF KINASE INHIBITOR; BILIRUBIN; COBIMETINIB; CREATININE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; URIC ACID; VEMURAFENIB; AZETIDINE DERIVATIVE; GDC-0973; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACNE; ADRENAL CANCER; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BILOMA; BODY WEIGHT DISORDER; CANCER GROWTH; CHLAMYDIAL PNEUMONIA; CHORIORETINOPATHY; COLITIS; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHEMA; FACIAL NERVE PARALYSIS; FAINTNESS; FATIGUE; FEMUR FRACTURE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEADACHE; HEMATEMESIS; HEMATURIA; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INTENTION TO TREAT ANALYSIS; KERATOACANTHOMA; KIDNEY FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MEASLES LIKE RASH; MELANOMA; MENTAL DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NECK PAIN; NEPHROLITHIASIS; OPEN STUDY; PAIN; PARESTHESIA; PELVIC PAIN; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PLEURA EFFUSION; PNEUMONIA; PRESYNCOPE; PRIORITY JOURNAL; PYELONEPHRITIS; QT PROLONGATION; RASH; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINOPATHY; SEBORRHEIC KERATOSIS; SEPSIS; SKIN CARCINOMA; SKIN INFECTION; SMALL INTESTINE OBSTRUCTION; STOMATITIS; SUICIDAL IDEATION; THORAX PAIN; TONSIL CANCER; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VERY ELDERLY; VOGT KOYANAGI SYNDROME; VOMITING; WOUND INFECTION; CANCER STAGING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; FOLLOW UP; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PATIENT SELECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; AZETIDINES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PIPERIDINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84904916223     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70301-8     Document Type: Article

References (22)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
2. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
3. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
4. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013, 31:1767-1774.
5. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
6. Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011, 6:e28973.
7. Carlino MS, Todd JR, Gowrishankar K, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014, 8:544-554.
8. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013, 31:482-489.
9. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012, 11:909-920.
10. Sosman JA, Daud A, Weber JS, et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9005.
11. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
12. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215.
13. King AJ, Arnone MR, Bleam MR, et al. Dabrafenib: preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One 2013, 8:e67583.
14. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
15. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
16. Rosen L, LoRusso P, Ma WW A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors [abstract]. Cancer Res 2011, 71(8 suppl). abstr 4716. 10.1158/1538-7445.AM2011-4716.
17. V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
18. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
19. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
20. Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. Proc Am Soc Clin Oncol 2014, 32(suppl). abstr 9011.
21. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
22. Kefford K Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 9029.